Cool Currents Vol. 08

For years, the cold chain industry has talked about the need for modernization; better monitoring, less spoilage, new innovations. In Q1 2026, the conversation moved toward mandated action.

Three things converged. DSCSA compliance has shifted from "can we meet the deadline?" to "can we actually operate in this new reality?" Large amounts of capital began pouring into the cold chain, changing the dynamics of ownership and infrastructure. And FSMA 204, arguably the largest traceability mandate the food cold chain has seen, hit its original January 2026 compliance window with full enforcement now set for July 2028. The buildout is already underway, and many organizations remain unprepared.

All three of these drivers point towards one destination: end-to-end proof of control. Real time, continuously, across every handoff, every mode change, every moment product is in transit. Temperature logs reviewed after the fact and compliance documentation assembled retroactively won't cut it anymore.

DSCSA moved from deadline to operating reality

What happened

The August 2025 deadline for wholesale distributor traceability compliance came and went. Now the industry is living inside the system it built, and the hard part is becoming clear. The challenge has shifted from "can we send EPCIS data?" to managing real-time exceptions when physical inventory exists but corresponding digital records don't. Based on HDA survey data, roughly 87% of manufacturers report active EPCIS implementation efforts, though readiness varies widely across the supply chain. Small dispensers face a November 27, 2026 deadline. The FDA has shown no interest in further extensions.

Why it matters

For cold chain operators, DSCSA compliance means every direct-to-patient finished drug now carries documentation requirements including temperature data, chain of custody, and product verification. Struggling organizations built systems that can't handle the messy, real-world exceptions that happen daily. Shipments that arrive before their digital records, returns that don't match the data, or products that change hands in ways the system wasn't designed to track. Exception handling is the new operational bottleneck.

Capital is reshaping who controls cold chain infrastructure

What happened

DHL Group committed EUR 2 billion through 2030 to pharmaceutical logistics, with roughly half directed at the Americas. This builds on several years of consolidation: CSafe Global's 2021 acquisition of Softbox Systems, Peli BioThermal's acquisition of Evo in October 2025 to expand its cryogenic capabilities, and UPS's $1.6 billion acquisition of Andlauer Healthcare Group in November 2025. The competitive landscape is consolidating into three tiers: mega-carriers investing billions (DHL, UPS Healthcare), specialized packaging leaders combining portfolios (CSafe-Softbox, Peli BioThermal), and technology-first platforms building on data and reusability.

Why it matters

When a single player announces it will invest $2.3 billion in pharmaceutical logistics it dramatically alters the economic dynamics for smaller players. They now face a decision; attempt to grow based on scale which becomes increasingly difficult with each passing quarter; or attempt to compete on capabilities that mega-carriers have not addressed yet. The consolidation also creates procurement complexity for shippers. Your cold chain partner from two years ago may now be owned by a different company, running different systems, with different priorities. The organizations navigating this well are asking harder questions during vendor qualification. Can you prove control at every handoff? Whose data am I trusting? Those questions matter more when the answer involves a corporate entity that didn't exist 18 months ago.

Consolidation tends to optimize for volume and standardization. The operators handling high-value, low-margin-for-error shipments still need solutions built for precision, not throughput. Clinical trials, cell therapies, and specialty biologics don't consolidate well. Capital doesn't automatically solve the control problem. Sometimes it makes it harder.

FSMA 204 forces a traceability buildout across food cold chain

What happened

The FDA's FSMA 204 Traceability Rule, which requires key data elements and critical tracking events to travel with products through the food supply chain, now has a compliance date of July 2028. However, Q1 2026 represented the beginning of the original compliance window and the data infrastructure build-out has begun. Every handoff, every mode change, every receiving event will need standardized, queryable documentation.

Why it matters

FSMA 204 effectively brings pharmaceutical-grade traceability expectations to food logistics. For organizations operating across both food and pharma cold chains, this creates convergence pressure: similar data requirements, similar audit expectations, similar infrastructure needs. The 30-month extension bought time, but not as much as it sounds. Building the traceability systems, integrating partners, and training teams takes years. And the GCCA panelists pointed to a deeper structural issue: nobody owns the whole chain. Warehouses optimize for warehouse metrics. Carriers optimize for carrier metrics. Until there's real economic or regulatory pressure to manage the cold chain as a single system, the gaps between handoffs will keep producing failures.

The food cold chain is learning what pharma discovered years ago: temperature is only part of the story. Traceability, auditability, and real-time intervention capability are becoming table stakes across every cold chain vertical. The organizations treating the July 2028 enforcement date as permission to wait will find themselves scrambling. The ones using this window to build actual visibility across handoff points will be in a fundamentally stronger position.

One number to know

70% of new pharmaceutical launches through 2027 are classified as specialty products (Cencora/industry data). The majority of these require some form of temperature-controlled handling, with biologics alone accounting for over half of the specialty pipeline. 

What we're watching in Q2

Direct-to-patient programs are quietly creating the most complex last-mile cold chain problem the industry has faced. UPS completed its $1.6 billion acquisition of Andlauer Healthcare Group in November, adding Canadian DTP specialist capabilities. SpotSee and Controlant announced a collaboration on last-mile shipment visibility in March. And CaryHealth launched a DTP program for Cipher Pharmaceuticals' Natroba in early April.

Each of these moves reflect the same reality: getting temperature-sensitive products to patients' homes is operationally harder than getting them to hospitals or clinics. The infrastructure assumptions, the monitoring requirements, the exception handling protocols are all different. Worth watching how quickly the industry adapts its cold chain systems to a world where the final destination is increasingly a front porch, not a loading dock.

One thing worth reading

"Why the U.S. Pharmaceutical Cold Chain Is Poised for Innovation" (Pharmaceutical Commerce, Q1 2026). A clear-eyed overview of the forces driving change in U.S. pharma logistics, from regulatory pressure to the biologics pipeline to infrastructure investment. Worth the read whether you're in pharma specifically or watching the cold chain evolve more broadly.

Chain Reaction 2025 is here

We spent months researching the forces that made 2025 a turning point for cold chain operations. Chain Reaction 2025 maps how $4.25M gene therapy doses, DSCSA enforcement, and a dry ice supply crunch are reshaping what operators need to be ready for. It includes a readiness scorecard you can use to benchmark your own operations.

Want a briefing call to walk through the findings most relevant to your operation? Reply to this email and we'll set it up.

Cool Currents is Artyc's quarterly perspective on what changed in the cold chain and why it matters. It's not a company update. It's a signal report for operators who don't have time to track everything themselves.